UNSPSC 51352004: Desogestrel

This classification denotes a therapeutic progestin with the molecular formula C22H30O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81K9V7M3A3, chemically known as 18,19-dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17alpha)- but generally known as desogestrel, which bears US NIH Compound Identifier 40973. European Medicines Agency schedules Desogestrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07003MIG.

UNSPSC 51352004 Desogestrel is a Commodity code covering the supply of this specific progestin-based contraceptive pharmaceutical to state and local government healthcare facilities and programs. State and local purchasing under this code centers on establishing supply agreements with pharmaceutical manufacturers and wholesalers to meet ongoing demand across Medicaid programs, public health clinics, corrections departments, and other government healthcare operations. Issuing bodies include state procurement offices acting as administrators of multi-state cooperative purchasing alliances, which leverage consolidated demand across multiple states and subordinate jurisdictions to negotiate volume pricing and standardized supply terms. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), is a primary repeat buyer in this category, executing cooperative purchasing vehicles that serve multiple states including Oregon.

The Minnesota Multistate Cooperative Purchasing Alliance issued a Request for Proposal (S1070000015802) on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products, including desogestrel and related contraceptive agents. Vendors must supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and maintain contractual relationships with at least two of the three. The RFP requires cGMP and Drug Supply Chain Security Act certification, EDI capability, commercial general liability insurance of $5 million per occurrence, and submission of detailed product information including National Drug Codes, SKUs, UPCs, and dosage configurations via Google Chrome and Excel-to-CSV format to MMCAP_Infuse.RFP@state.mn.us. Evaluation weighs price competitiveness at 75 percent, with the contract term running two years for new responders and optional extensions at MMCAP's discretion, and awarded products must be available in the marketplace by May 15, 2026.